Lin T.-Y.Cheng Y.-C.Yang H.-C.WEI-CHOU LINWang C.-C.Lai P.-L.Shieh S.-Y.2022-03-042022-03-0420120950-9232https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863718409&doi=10.1038%2fonc.2011.491&partnerID=40&md5=5e1f5339ad2bfc57951d59d1e48f99cchttps://scholars.lib.ntu.edu.tw/handle/123456789/596151The B-cell translocation gene 3 (BTG3) is a member of the antiproliferative BTG gene family and a downstream target of p53. BTG3 also binds and inhibits E2F1. Although it connects functionally two major growth-regulatory pathways, the physiological role of BTG3 remains largely uncharacterized. Here, we present evidence that loss of BTG3 in normal cells induced cellular senescence, which was correlated with enhanced ERK-AP1 signaling and elevated expression of the histone H3K27me3 demethylase JMJD3/KDM6B, leading to acute induction of p16 INK4a. Importantly, we also found that BTG3 expression is specifically downregulated in prostate cancer, thus providing a physiological link with human cancers. Our data suggest that BTG3 may have a fail-safe role against tumorigenic progression. ? 2012 Macmillan Publishers Limited All rights reserved.BTG3; cellular senescence; ERK; JMJD3/KDM6B[SDGs]SDG3cyclin dependent kinase inhibitor 2A; histone demethylase; histone H3K27me3 demethylase; mitogen activated protein kinase; transcription factor AP 1; unclassified drug; article; B cell translocation gene 3; controlled study; DNA sequence; down regulation; fibroblast; gene expression; gene loss; human; human cell; human tissue; phenotype; priority journal; promoter region; prostate cancer; protein expression; senescence; signal transduction; transcription initiation; tumor suppressor gene; upregulation; Cell Aging; Cell Line; Cyclin-Dependent Kinase Inhibitor p16; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Humans; Jumonji Domain-Containing Histone Demethylases; Male; Prostatic Neoplasms; Proteins; Signal Transduction; Transcription Factor AP-1; Transcriptional Activation; Tumor Suppressor Proteinsjournal article10.1038/onc.2011.491220203312-s2.0-84863718409